Beam Therapeutics Inc. (BEAM): restructuring charge — Beam cuts ~20% workforce (100 roles), focuses on sickle cell, AATD, extends cash runway into 2026

Beam Therapeutics Inc.

Reduces headcount by ~100 employees (20%), expects $6.6M in Q4 2023 severance costs.
Prioritizes BEAM-101, ESCAPE, and in vivo sickle cell programs; BEAM-302 for AATD.
Explores partnerships for BEAM-201 and other CAR-T programs; pauses hepatitis B program.
Cash, equivalents, and securities of $1.1B (June 30, 2023) expected to fund operations into 2026.
Strategic restructuring aims to streamline operations and focus on near-term value drivers.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Beam Therapeutics Inc. announced a restructuring with charges of approximately $6.6 million affecting not explicitly stated per segment, but described as portfolio prioritization and strategic restructuring of Beam Therapeutics (approximately 100 positions, or about 20% of its workforce).

Type: restructuring
Charge: approximately $6.6 million
Affected area: not explicitly stated per segment, but described as portfolio prioritization and strategic restructuring of Beam Therapeutics
Headcount: approximately 100 positions, or about 20% of its workforce

Exact text from the filing

the Company expects to reduce its employee headcount by approximately 100 positions, or about 20% of its workforce. The Company expects to incur one-time costs of approximately $6.6 million in the fourth quarter of 2023 in connection with the workforce reduction. These costs consist primarily of cash expenditures related to severance payments. The Company estimates

View on SEC.gov

Browse all restructurings & charges →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-258963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.